ConductScience.org, home

Paper648565

Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease.

Tattersall MH and 5 others. Eur J Cancer (1965), 1978. Cited by 104 papers, by iCite.

Cite this record

ConductScience Library. Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease. Papers, record 648565. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/648565

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease.
PubMed
Journal
Eur J Cancer (1965)
PubMed
Year
1978
PubMed
Publication types
Clinical Trial, Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
104
iCite
Relative citation ratio, by iCite
5.08
iCite
Revised in PubMed
2019-09-07
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tattersall MHM H
2Jarman MM
3Newlands ESE S
4Holyhead LL
5Milstead RAR A
6Weinberg AA

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MelphalanMajor topic
NeoplasmsMajor topic
Administration, Oral
Adult
Aged
Female
Half-Life
Humans
Injections, Intravenous
Male
Middle Aged
Time Factors

Source PubMed

Download CSV of topics

Cited by24

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 104 citations.

PMIDTitleJournalYearIn PapersSource
22922522Fifty years of melphalan use in hematopoietic stem cell transplantation.Biol Blood Marrow Transplant2013https://conductscience.org/library/papers/22922522PubMed
16430310Mass balance studies, with a focus on anticancer drugs.Clin Pharmacokinet2006https://conductscience.org/library/papers/16430310PubMed
15752378Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation.Br J Clin Pharmacol2005https://conductscience.org/library/papers/15752378PubMed
8462127Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/8462127PubMed
7307234The combination of melphalan with prednisolone. Anti-tumor effect and normal tissue toxicity in laboratory systems.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/7307234PubMed
7296753Melphalan estimation by quantitative thin-layer chromatography. Observations on melphalan hydrolysis in vitro and pharmacokinetics in rabbits.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/7296753PubMed
7139852Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7139852PubMed
7105381In vitro degradation of L-phenylalanine mustard (L-PAM).Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7105381PubMed
6994913The practical benefits of pharmacokinetics in the use of antineoplastic agents.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/6994913PubMed
6705135Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma.Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6705135PubMed
6678879Pharmacokinetics of high dose melphalan.Invest New Drugs1983https://conductscience.org/library/papers/6678879PubMed
3948305The effect of food on oral melphalan absorption.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3948305PubMed
3948304Pharmacokinetics of high-dose melphalan in children and adults.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3948304PubMed
3888428Anticancer drug pharmacodynamics.Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/3888428PubMed
3690803Variability of tumor response to chemotherapy. I. Contribution of host heterogeneity.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3690803PubMed
3594717The effect of dietary amino acids on the gastrointestinal absorption of melphalan and chlorambucil.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3594717PubMed
3516430Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3516430PubMed
3349564A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma.Cancer Chemother Pharmacol1988https://conductscience.org/library/papers/3349564PubMed
3311530Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.Clin Pharmacokinet1987https://conductscience.org/library/papers/3311530PubMed
3191937The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.Eur J Clin Pharmacol1988https://conductscience.org/library/papers/3191937PubMed

See all 24 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/648565

GET https://conductscience.org/api/papers/v1/648565/cited_by?page=2